Please use this identifier to cite or link to this item:
https://doi.org/10.1007/s00280-003-0637-5
DC Field | Value | |
---|---|---|
dc.title | Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: A Cancer Therapeutics Research Group study | |
dc.contributor.author | Soo, R.A. | |
dc.contributor.author | Lim, H.L. | |
dc.contributor.author | Wang, L.Z. | |
dc.contributor.author | Lee, H.S. | |
dc.contributor.author | Millward, M.J. | |
dc.contributor.author | Tok, L.T. | |
dc.contributor.author | Lee, S.C. | |
dc.contributor.author | Lehnert, M. | |
dc.contributor.author | Goh, B.C. | |
dc.date.accessioned | 2014-10-29T01:56:47Z | |
dc.date.available | 2014-10-29T01:56:47Z | |
dc.date.issued | 2003-08-01 | |
dc.identifier.citation | Soo, R.A., Lim, H.L., Wang, L.Z., Lee, H.S., Millward, M.J., Tok, L.T., Lee, S.C., Lehnert, M., Goh, B.C. (2003-08-01). Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: A Cancer Therapeutics Research Group study. Cancer Chemotherapy and Pharmacology 52 (2) : 153-158. ScholarBank@NUS Repository. https://doi.org/10.1007/s00280-003-0637-5 | |
dc.identifier.issn | 03445704 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/106214 | |
dc.description.abstract | Purpose: To determine the maximally tolerated dose (MTD) of gemcitabine administered at a fixed dose-rate of 10 mg/m2 per min in combination with fixed dose carboplatin, to evaluate the toxicity of this regimen and to determine the pharmacokinetics of plasma gemcitabine. Methods: Patients with advanced stage non-small-cell lung cancer (NSCLC) received carboplatin (AUC 5) on day 1 followed by gemcitabine at a fixed dose rate of 10 mg/m2 per min in escalating durations of infusion on days 1 and 8 every 21 days. Pharmacokinetic sampling was obtained on day 1, cycle 1 of treatment. Results: A total of 15 patients received carboplatin and gemcitabine in cohorts of three to six patients at three dose levels. The doses of gemcitabine studied were 600, 750, and 900 mg/m2. The MTD was reached at 900 mg/m2. Dose-limiting toxicities were thrombocytopenia and liver failure, and with repeated dosing neutropenia was commonly observed. The recommended phase II dose of gemcitabine was 750 mg/m2. Partial responses were observed at 600 and 750 mg/m2 of gemcitabine. Plasma gemcitabine did not reach steady state except in one patient with the durations of infusion studied. Plasma concentrations, however, were above 10 μmol/l between 20 and 90 min in all patients. Conclusions: Gemcitabine administered as a 75-min infusion at a fixed dose rate of 10 mg/m2/min on days 1 and 8 in combination with carboplatin on day 1 every 21 days is tolerable and active in NSCLC. Pharmacokinetic studies demonstrated that the target plasma gemcitabine concentration above 10 μmol/l was achieved. Further studies are warranted to compare this regimen against standard regimens of carboplatin and gemcitabine. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1007/s00280-003-0637-5 | |
dc.source | Scopus | |
dc.subject | Fixed dose rate | |
dc.subject | Gemcitabine | |
dc.subject | Non-small-cell lung cancer | |
dc.subject | Phase I study | |
dc.type | Article | |
dc.contributor.department | PHARMACY | |
dc.description.doi | 10.1007/s00280-003-0637-5 | |
dc.description.sourcetitle | Cancer Chemotherapy and Pharmacology | |
dc.description.volume | 52 | |
dc.description.issue | 2 | |
dc.description.page | 153-158 | |
dc.description.coden | CCPHD | |
dc.identifier.isiut | 000184297800010 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.